Toludesvenlafaxine is described as an SNDRI and prodrug to desvenlafaxine.[2] However, unlike desvenlafaxine, which has in vitroIC50Tooltip half-maximal inhibitory concentration values of 53 nM and 538 nM for inhibition of serotonin and norepinephrinereuptake, respectively, toludesvenlafaxine has respective in vitro IC50 values of 723 nM, 763 nM, and 491 nM for serotonin, norepinephrine, and dopamine reuptake inhibition.[2] As such, toludesvenlafaxine appears to be a more balanced reuptake inhibitor of serotonin, norepinephrine, and dopamine than desvenlafaxine.[2]
As of July 2018, toludesvenlafaxine is in preregistration for the treatment of depression in the United States, the European Union, and Japan.[1] As of January 2023, it is also in phase 3 clinical trials for the treatment of generalized anxiety disorder.[1] In March 2020, the United States Food and Drug Administration accepted Luye Pharma's New Drug Application for toludesvenlafaxine, which remains under review.[1][5] In November 2022, toludesvenlafaxine was approved for the treatment of depression in China under the brand name Ruoxinlin.[6][7]
^ abcdZhang R, Li X, Shi Y, Shao Y, Sun K, Wang A, et al. (2014). "The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats". PLOS ONE. 9 (3): e91775. Bibcode:2014PLoSO...991775Z. doi:10.1371/journal.pone.0091775. PMC3948889. PMID 24614602.
^Dale E, Bang-Andersen B, Sánchez C (May 2015). "Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs". Biochemical Pharmacology. 95 (2): 81–97. doi:10.1016/j.bcp.2015.03.011. PMID 25813654.
^Completion of Phase 1 Clinical Studies of Ansofaxine Hydrochloride Extended Release Tablets (LY03005) in the U.S.
^"Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets". BioSpace. Retrieved 2022-02-08.
^"Luye Pharma's Class 1 Innovative Antidepressant Ruoxinlin® Approved for Launch in China - Press Releases - Luye Pharma Group". www.luye.cn. Retrieved 2022-12-04.
ansofaxine, toludesvenlafaxine, also, formerly, known, ansofaxine, sold, under, brand, name, ruoxinlin, antidepressant, which, approved, treatment, major, depressive, disorder, china, also, under, development, other, countries, like, united, states, serotonin,. Toludesvenlafaxine also formerly known as ansofaxine and sold under the brand name Ruoxinlin is an antidepressant which is approved for the treatment of major depressive disorder in China 1 It is also under development for use in other countries like the United States 1 It is a serotonin norepinephrine dopamine reuptake inhibitor SNDRI and was developed by Luye Pharma Group 1 2 3 4 AnsofaxineClinical dataOther namesLY03005 LPM570065 4 Methylbenzoate desvenlafaxineRoutes ofadministrationBy mouthIdentifiersIUPAC name 4 2 Dimethylamino 1 1 hydroxycyclohexyl ethyl phenyl 4 methylbenzoateCAS Number916918 84 8 hydrochloride PubChem CID56955395ChemSpider13114670UNIIV6Z6K3OQX4Chemical and physical dataFormulaC 24H 31N O 3Molar mass381 516 g mol 13D model JSmol Interactive imageSMILES Cc1ccc cc1 C O Oc2ccc cc2 C CN C C C3 CCCCC3 OInChI InChI 1S C24H31NO3 c1 18 7 9 20 10 8 18 23 26 28 21 13 11 19 12 14 21 22 17 25 2 3 24 27 15 5 4 6 16 24 h7 14 22 27H 4 6 15 17H2 1 3H3Key QKYBZJLEMOZFFU UHFFFAOYSA N Toludesvenlafaxine is described as an SNDRI and prodrug to desvenlafaxine 2 However unlike desvenlafaxine which has in vitro IC50Tooltip half maximal inhibitory concentration values of 53 nM and 538 nM for inhibition of serotonin and norepinephrine reuptake respectively toludesvenlafaxine has respective in vitro IC50 values of 723 nM 763 nM and 491 nM for serotonin norepinephrine and dopamine reuptake inhibition 2 As such toludesvenlafaxine appears to be a more balanced reuptake inhibitor of serotonin norepinephrine and dopamine than desvenlafaxine 2 As of July 2018 toludesvenlafaxine is in preregistration for the treatment of depression in the United States the European Union and Japan 1 As of January 2023 it is also in phase 3 clinical trials for the treatment of generalized anxiety disorder 1 In March 2020 the United States Food and Drug Administration accepted Luye Pharma s New Drug Application for toludesvenlafaxine which remains under review 1 5 In November 2022 toludesvenlafaxine was approved for the treatment of depression in China under the brand name Ruoxinlin 6 7 References edit a b c d e f Toludesvenlafaxine extended release Luye Pharma AdisInsight Springer Nature Switzerland AG a b c d Zhang R Li X Shi Y Shao Y Sun K Wang A et al 2014 The effects of LPM570065 a novel triple reuptake inhibitor on extracellular serotonin dopamine and norepinephrine levels in rats PLOS ONE 9 3 e91775 Bibcode 2014PLoSO 991775Z doi 10 1371 journal pone 0091775 PMC 3948889 PMID 24614602 Dale E Bang Andersen B Sanchez C May 2015 Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs Biochemical Pharmacology 95 2 81 97 doi 10 1016 j bcp 2015 03 011 PMID 25813654 Completion of Phase 1 Clinical Studies of Ansofaxine Hydrochloride Extended Release Tablets LY03005 in the U S Luye Pharma Releases Top Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended Release Tablets BioSpace Retrieved 2022 02 08 Luye Pharma s Class 1 Innovative Antidepressant Ruoxinlin Approved for Launch in China Press Releases Luye Pharma Group www luye cn Retrieved 2022 12 04 R amp D Luye Pharma Group www luye cn Retrieved 2022 10 06 External links editToludesvenlafaxine extended release AdisInsight nbsp This drug article relating to the nervous system is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Ansofaxine amp oldid 1182642270, wikipedia, wiki, book, books, library,
